[209+ Pages Report] According to Facts & Factors, the global benign prostatic hyperplasia (BPH) treatment devices market size in terms of revenue was valued at around USD 1520.17 million in 2023 and is expected to reach a value of USD 3240.33 million by 2032, growing at a CAGR of roughly 8.77% from 2024 to 2032. The global benign prostatic hyperplasia (BPH) treatment devices market is projected to grow at a significant growth rate due to several driving factors.
Benign prostatic hyperplasia (BPH) treatment devices are medical devices used to treat the enlargement of the prostate gland in men. The prostate gland is a small, walnut-shaped gland that sits just below the bladder and surrounds the urethra. As men age, the prostate gland can enlarge, which can narrow the urethra and cause urinary problems.
There are a number of different BPH treatment devices available, each with its own advantages and disadvantages. The best device for a particular man will depend on the severity of his symptoms, his overall health, and his preferences.
The global benign prostatic hyperplasia (BPH) treatment devices market is segmented based on product, procedure type, end user, and region.
Based on Product, the global benign prostatic hyperplasia (BPH) treatment devices market is bifurcated into resectoscopes, urology lasers, radiofrequency ablation devices, prostatic stents and implants. Resectoscopes are instruments used in Transurethral Resection of the Prostate (TURP), a common surgical procedure for BPH. Urology Lasers segment includes various lasers used for minimally invasive BPH procedures like laser enucleation of the prostate. Radiofrequency Ablation Devices use radiofrequency energy to destroy prostate tissue causing BPH. Prostatic Stents and Implants includes devices like urethral stents to open up the blocked urinary passage and implants to support the prostate.
Based on Procedure Type, the global benign prostatic hyperplasia (BPH) treatment devices market is categorized into transurethral microwave therapy (TUMT), transurethral resection of the prostate (TURP), transurethral needle ablation (TUNA), laser surgery, and urolift surgery. Transurethral Microwave Therapy (TUMT) uses microwave energy to heat and destroy prostate tissue. Transurethral Resection of the Prostate (TURP) is Surgical removal of prostate tissue with a resectoscope. Transurethral Needle Ablation (TUNA) uses radiofrequency needles to ablate prostate tissue. Laser Surgery utilizes lasers for minimally invasive prostate tissue removal. Urolift Surgery Implants tiny devices to hold the prostate in place and open the urethra.
Based on End User, the global benign prostatic hyperplasia (BPH) treatment devices market is categorized into hospitals, ambulatory surgical centers (ASCs), and clinics. Hospitals are primary users of BPH treatment devices for surgeries and procedures. Ambulatory Surgical Centers (ASCs) is outpatient clinics equipped for minimally invasive BPH procedures. In Clinics, physician offices may offer some BPH procedures using relevant devices.
In May 2023, Teleflex Incorporated announced significant research findings regarding the long-term effectiveness of the prostatic urethral lift procedure using the UroLift System. The data revealed that this procedure had fewer complications compared to other traditional minimally invasive procedures for benign prostatic hyperplasia (BPH).
In May 2021, Olympus Corporation announced the acquisition of Medi-Tate, a medical equipment maker.
Report Attribute |
Details |
Market Size in 2023 |
USD 1,520.17 Million |
Projected Market Size in 2032 |
USD 3,240.33 Million |
CAGR Growth Rate |
8.77% CAGR |
Base Year |
2023 |
Forecast Years |
2024-2032 |
Key Market Players |
Boston Scientific Corporation, Coloplast Corp, Cook Medical, Endo Pharmaceuticals Inc., Karl Storz, Medifocus, Olympus America, PROCEPT BioRobotics Corporation, Richard Wolf GmbH, Teleflex Incorporated, Urotronic, biolitec AG, and Others. |
Key Segment |
By Product, By Procedure Type, By End User, and By Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East &, Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
North America currently holds the dominant position in the BPH treatment devices market due to factors like high disposable income, established healthcare infrastructure, and early adoption of new technologies. The CAGR (Compound Annual Growth Rate) for this region is expected to be steady but slightly lower compared to other regions.
Europe is another major market for BPH treatment devices due to its large aging population and well-developed healthcare systems. The European market is projected to have a healthy CAGR.
Asia Pacific is expected to witness the fastest growth in the BPH treatment devices market due to a rapidly aging population, rising healthcare expenditure, and increasing awareness about BPH. The CAGR for this region is anticipated to be the highest.
Some of the major players in the global benign prostatic hyperplasia (BPH) treatment devices market include:
The global benign prostatic hyperplasia (BPH) treatment devices market is segmented as follows:
Copyright © 2023 - 2024, All Rights Reserved, Facts and Factors